Exhibit 99.1 HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years On Track to Submit sNDA for Pitolisant in Idiopathic Hypersomnia (IH) in Q4 2024 Based on Updated Strong and Sustained Efficacy Data from Long-Term Extension Study N ...

The market expects Harmony Biosciences Holdings, Inc. (HRMY) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which ...

Harmony Biosciences Holdings, Inc. (HRMY) shares rallied 6.7% in the last trading session to close at $39.79. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.2% gain over the past four weeks. Last month, the company announced robust financial results for the second quarter of 2024. Harmony's approved product, Wakix (pitolisant) is driving revenues while the company is making good progress with the studies o ...

Harmony Biosciences Holdings, Inc. (HRMY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and follo ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Regeneron (REGN) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a prove ...

Core Viewpoint - Harmony Biosciences (HRMY) is identified as a strong value stock, currently undervalued compared to its industry peers, with favorable valuation metrics and a positive earnings outlook [3][7]. Valuation Metrics - HRMY has a Price-to-Book (P/B) ratio of 3.80, which is lower than the industry average of 4.72, indicating potential undervaluation [4]. - The Price-to-Sales (P/S) ratio for HRMY stands at 3.15, significantly below the industry average of 6.69, suggesting that the stock may be undervalued based on revenue [5]. - HRMY's Price-to-Cash Flow (P/CF) ratio is 14.95, compared to the industry average of 20.61, further supporting the notion of undervaluation [6]. Historical Performance - Over the past 52 weeks, HRMY's P/B ratio has fluctuated between a high of 4.83 and a low of 2.34, with a median of 3.66, indicating variability in market perception [4]. - The P/CF ratio for HRMY has ranged from a low of 6.65 to a high of 15.28, with a median of 11.14, reflecting its cash flow performance over the past year [6].

Company Overview - Harmony Biosciences Holdings, Inc. specializes in developing treatments for rare neurological diseases that are often overlooked by others [2] - The company was established in 2017 by Paragon Biosciences, LLC and is headquartered in Plymouth Meeting, PA [2] - Harmony's team is composed of experts from various disciplines, driven by the belief that innovative science leads to therapeutic possibilities for patients [2] Upcoming Events - Harmony's management team will participate in the Wells Fargo 2024 Healthcare Conference in Boston on September 5, 2024, at 9:30 a.m. ET [1] - The company will also take part in the 2024 Cantor Global Healthcare Conference in New York City on September 17, 2024, at 3:05 p.m. ET [1] - A webcast of the fireside chats from these conferences will be available on Harmony's investor page [1]

| --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------|-------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | | ...

Core Viewpoint - Harmony Biosciences Holdings, Inc. (HRMY) shows a significant improvement in earnings outlook, making it an attractive investment option as analysts continue to raise earnings estimates for the company [1][2]. Earnings Estimates - Analysts' optimism regarding Harmony Biosciences' earnings prospects is leading to higher estimates, which is expected to positively impact the stock price [2]. - The Zacks Rank system indicates a strong correlation between earnings estimate revisions and stock price movements, with Zacks 1 Ranked stocks averaging a +25% annual return since 2008 [3]. Current-Quarter Estimates - For the current quarter, Harmony Biosciences is projected to earn $0.60 per share, reflecting a -4.76% change from the previous year [4]. - The Zacks Consensus Estimate for the current quarter has increased by 5.26% over the last 30 days, with one estimate rising and another falling [4]. Current-Year Estimates - The company is expected to earn $2.19 per share for the full year, representing a +2.82% change from the prior year [5]. - Over the past month, two estimates have been revised upward for Harmony Biosciences, while one estimate was revised downward, resulting in an 8.6% increase in the consensus estimate [5]. Zacks Rank - Harmony Biosciences currently holds a Zacks Rank 2 (Buy) due to favorable estimate revisions, indicating strong potential for outperformance compared to the S&P 500 [6]. - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the market [6]. Stock Performance - Harmony Biosciences shares have increased by 7.9% over the past four weeks, suggesting investor confidence in the company's earnings growth prospects [7].

Company Overview - Harmony Biosciences is a commercial stage biopharma company focused on developing treatments for rare and neurological diseases, with one approved product, WAKIX (pitolisant), for excessive daytime sleepiness in narcolepsy patients [2][11] - The company has a market capitalization of approximately $1.9 billion and its stock trades around $34.00 per share [2] Recent Developments - Harmony has received favorable analyst coverage and recently gained approval for a label extension for WAKIX, which now includes pediatric patients aged 6 years and older [12] - The company has made several acquisitions to expand its pipeline, including Epygenix Therapeutics for $35 million, which adds drug candidates targeting rare epilepsy conditions [8][9] - Harmony also acquired exclusive rights to Bioprojet's sleep disorder therapy, TPM-1116, for $25.5 million, and purchased Zynerba Pharmaceuticals for $200 million, which includes Zygel in Phase 3 development for Fragile X Syndrome [9][10] Financial Performance - For Q2 2024, Harmony reported GAAP earnings of $0.20 per share on revenues of $172.8 million, with WAKIX sales increasing by 29% year-over-year [11] - Operating expenses rose significantly to $119.3 million, primarily due to increased R&D expenses of $63.6 million as the company advances its pipeline [11] - The company maintains a FY2024 sales guidance of $700 million, representing a 22% increase over FY2023 [12] Analyst Sentiment - Analyst opinions are mixed, with Goldman Sachs maintaining a Sell rating, citing slowing patient growth, while Mizuho Securities, Needham, and Oppenheimer reiterated Buy ratings with price targets ranging from $52 to $56 [14] - The company ended the first half of 2024 with nearly $435 million in cash and marketable securities, alongside long-term debt of just over $170 million [14] Future Outlook - Analysts project profits to rise slightly to $2.18 per share in FY2024, with significant growth expected in FY2025, estimating profits of $3.67 per share on sales growth of 18% [15] - Management believes that the newly acquired assets could add $1 billion to $2 billion in peak sales if developed successfully, with WAKIX having at least $1 billion in peak potential revenues [15]